Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Peptic Ulcer

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity.

Frontiers in immunology·2026

Same author

Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultation.

Vaccine·2026

Same author

Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial.

The Lancet. Infectious diseases·2026

Same author

Co-administration of oral killed whole-cell recombinant cholera toxin B-subunit vaccine (WC-rCTB) and live Salmonella Typhi Ty21a vaccine: a prospective randomized open-label trial.

Journal of travel medicine·2026

Same author

Long-term follow-up of antibody and T-cell responses after COVID-19 mRNA vaccination in infection-naïve and infected individuals with focus on breakthrough infections.

Infectious diseases (London, England)·2026

Same author

Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Lung cancer (Amsterdam, Netherlands)·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Progress in vaccine development against Helicobacter pylori.

Ann-Mari Svennerholm¹, Anna Lundgren

¹Department of Microbiology and Immunology, Institute of Biomedicine, Göteborg University, Göteborg, Sweden. ann-mari.svennerholm@microbio.gu.se

FEMS Immunology and Medical Microbiology

|April 20, 2007

Summary

Developing an effective Helicobacter pylori vaccine is crucial due to high disease prevalence and rising antibiotic resistance. Further research is needed to identify protective antigens and optimal immunization strategies for humans.

More Related Videos

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

Area of Science:

Microbiology
Immunology
Vaccinology

Background:

High prevalence of Helicobacter pylori infections globally, especially in developing nations.
Increasing antibiotic resistance in H. pylori clinical isolates necessitates alternative control strategies.
Existing knowledge gaps in protective immune mechanisms against H. pylori.

Purpose of the Study:

To review promising candidate vaccines and immunization strategies against H. pylori.
To explore immune responses correlated with protection in animal models and human patients.
To identify key antigens and regimens for effective human vaccination.

Main Methods:

Literature review of recent vaccine candidates and immunization studies.
Analysis of experimental animal studies investigating protective immunity.
Comparative analysis of immune responses in H. pylori-infected patients with varying disease outcomes (ulcers, cancer) versus asymptomatic carriers.

Main Results:

Several promising vaccine candidates and immunization strategies are under development.
Studies have identified potential immune responses linked to protection in animal models.
Distinct immune responses are associated with protection against H. pylori-related diseases in humans.

Conclusions:

Clarification of the primary protective immune mechanisms against H. pylori is essential.
Identification of a cocktail of potent protective antigens or recombinant strains is needed.
Development of an effective vaccination regimen that elicits robust human immune responses remains a key goal.